biotech stocks Archives

Conceptual Serina Therapeutics laboratory illustration with neurons, drug-delivery imagery and a display highlighting a potential 2027 clinical milestone.

Serina Therapeutics: A Parkinson’s Bet Where Delivery Is the Message -( $ABBV $SER )

by John F. Heerdink, Jr. 2 days ago 86Views 0Likes

As SER-252 advances into its second dose cohort, Serina is building a case that improving how a medicine reaches patients can be as consequential as discovering the medicine itself. Serina Therapeutics, Inc. (NYSE American: SER) is pursuing an appealing proposition in biotechnology:…

Futuristic biotech illustration featuring a glowing digital bull, rising market arrows, and research pathways labeled Disc Medicine, Arcutis and Parabilis leading toward a biotechnology innovation hub.

Biotech Bulls Find Fresh Fuel as Disc Medicine, Arcutis and Parabilis Advance Their Investment Cases -( $ARQT $BBC $IRON $PBLS )

by John F. Heerdink, Jr. October 19, 2026 419Views 0Likes

A pivotal trial victory, a growing dermatology franchise and an approaching oncology catalyst put IRON, ARQT and PBLS in the spotlight, while the BBC biotech ETF offers a broader view of the sector. October 19, 2026 Biotechnology investors are being offered three…

Scientists in a modern biotechnology laboratory review digital DNA models, molecular structures and drug development charts.

Merck’s $1.3 Billion Silence Deal Puts Precision Biotech in Focus as Serina and Eupraxia Advance -( $BBC $EPRX $IBB $MKKGY $MRK $SER $SLN $XBI )

by John F. Heerdink, Jr. October 19, 2026 346Views 0Likes

A substantial takeover premium highlights the value of differentiated medicines, while Serina Therapeutics and Eupraxia Pharmaceuticals approach clinical milestones of their own. October 19, 2026 Biotechnology investors received a rather emphatic reminder Monday that pharmaceutical innovation can still command a premium, even…

Biotech professionals collaborate in a modern laboratory with molecular models, digital research displays and blue and green upward arrows symbolizing growth.

Moderna and Novavax Rally: ‘Cancer Vaccine’ Stocks Get a Shot of Investor Confidence -( $IBB $MRK $MRNA $NVAX $SNY $XBI )

by John F. Heerdink, Jr. October 10, 2026 592Views 0Likes

Clinical progress, a proposed U.S. research initiative and vaccine licensing economics strengthen the bull case. Biotechnology investors are finding fresh reasons to look beyond the pandemic trade. Moderna (NASDAQ: MRNA), Novavax (NASDAQ: NVAX) and Merck (NYSE: MRK) rallied on October 9 as…

Comic-book-style illustration highlighting pharma, space and AI investment themes: a Bayer research lab in Ohio, a SpaceX rocket launching from an Ohio-inspired Starbase, and Eupraxia displayed over an AI-powered global network, beneath the headline “Pharma, Rockets and AI: Why Bayer, SpaceX and Eupraxia Have Investors Looking Up.”

Pharma, Rockets and AI: Why Bayer, SpaceX and Eupraxia Have Investors Looking Up -( $BAYRY $EPRX $GOOGL $SPCX $TSLX )

by John F. Heerdink, Jr. October 3, 2026 372Views 0Likes

The Market’s Growth Engines Are Getting Physical Wall Street has spent years rewarding promises around artificial intelligence, advanced medicine and space infrastructure. This week, the narrative acquired something investors usually appreciate even more: concrete evidence of execution. Bayer AG (OTC: BAYRY) is…

Business analysts review Eupraxia Pharmaceuticals’ EP-104GI clinical data, including symptom reduction and histological-response visuals, alongside an investment calendar highlighting the anticipated December 2026 RESOLVE trial milestone.

Eupraxia’s One-Year EoE Data Draw Fresh Analyst Attention Ahead of December Catalyst – ( $EPRX $IBB $SNY $XBI )

by John F. Heerdink, Jr. October 2, 2026 744Views 0Likes

Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX; TSX: EPRX) has added a new layer of clinical durability to its EoE investment case, and Wall Street’s bullish coverage is becoming harder to overlook. The company’s latest 52-week EP-104GI data, including 64% clinical remission among evaluable higher-dose…

Promotional graphic for a Tribe Public CEO dinner event featuring Eupraxia Pharmaceuticals (NASDAQ: EPRX), James Helliwell, M.D., and the company’s 52-week EP-104GI clinical update for eosinophilic esophagitis. The image illustrates localized treatment at week zero, durable symptom control through week 52, and a stylized upward EPRX market graphic.

Eupraxia’s One-and-Done EoE Strategy Gains a 52-Week Tailwind -( $EPRX $IBB $REGN $SNY $XBI )

by John F. Heerdink, Jr. September 30, 2026 468Views 0Likes

Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX; TSX: EPRX) has added a potentially important chapter to its eosinophilic esophagitis, or EoE, story: a single administration of its investigational localized therapy, EP-104GI, continued to show clinical-remission signals at 52 weeks in the highest-dose cohorts of the…

Iovance Biotherapeutics revenue guidance display in a modern trading-floor setting, highlighting rising Amtagvi demand, a Goldman Sachs Buy rating, and NASDAQ market screens.

Iovance Biotherapeutics Raises 2026 Revenue Guidance as Amtagvi Demand Accelerates & Goldman Resumes Coverage – ( $GS $IOVA $XBI $IBB )

by John F. Heerdink, Jr. September 30, 2026 490Views 0Likes

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) delivered the sort of update growth investors prefer: higher guidance, record revenue, expanding treatment access, and a more visible route toward operating leverage. Shares climbed sharply after the company lifted its 2026 revenue outlook, suggesting Wall Street is…

Investor-focused healthcare graphic showing a laboratory scene, a clinician holding a drug-delivery device, a glowing brain illustration, molecular imagery and a city skyline. The image highlights AbbVie Inc. (NYSE: ABBV) receiving FDA approval for JUVMO (tavapadon) for Parkinson’s disease and positions Serina Therapeutics Inc. (NYSE American: SER) and its SER-252 program as a potential next-generation therapy opportunity in advanced Parkinson’s disease.

AbbVie’s JUVMO Approval Puts Parkinson’s Innovation Back in Motion And Serina Therapeutics Has a Timely Opening -( $ABBV $AMRX $SER $SUPN $IBB $XBI )

by John F. Heerdink, Jr. September 29, 2026 548Views 0Likes

AbbVie Inc. (NYSE: ABBV) has secured (Sept. 28) FDA approval for JUVMO™ (tavapadon), a new once-daily Parkinson’s therapy, adding an important fresh option to a market long defined by the delicate art of managing motor symptoms, “OFF” time, dyskinesia and medication burden. For Serina…

Illustration of a futuristic biotech bear in a forest alongside a princess and armored knight, symbolizing the growing investment opportunity in durable drug-delivery therapies for retinal disease, eosinophilic esophagitis, and Parkinson’s disease.

Biotech’s Durability Trade Is Getting Interesting: Kodiak, Eupraxia and Serina Put the Burden of Treatment in Focus -( $ABBV $EPRX $IBB $KOD $SER $XBI )

by John F. Heerdink, Jr. September 28, 2026 563Views 0Likes

The biotech market has long rewarded breakthrough efficacy. Increasingly, it is also rewarding something patients and physicians understand with unusual clarity: less treatment burden. Fresh clinical updates from Kodiak Sciences Inc. (NASDAQ: KOD), Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX), and Serina Therapeutics Inc. (NYSE…

Tag: biotech stocks

Serina Therapeutics: A Parkinson’s Bet Where Delivery Is the Message -( $ABBV $SER )

Biotech Bulls Find Fresh Fuel as Disc Medicine, Arcutis and Parabilis Advance Their Investment Cases -( $ARQT $BBC $IRON $PBLS )

Merck’s $1.3 Billion Silence Deal Puts Precision Biotech in Focus as Serina and Eupraxia Advance -( $BBC $EPRX $IBB $MKKGY $MRK $SER $SLN $XBI )

Moderna and Novavax Rally: ‘Cancer Vaccine’ Stocks Get a Shot of Investor Confidence -( $IBB $MRK $MRNA $NVAX $SNY $XBI )

Pharma, Rockets and AI: Why Bayer, SpaceX and Eupraxia Have Investors Looking Up -( $BAYRY $EPRX $GOOGL $SPCX $TSLX )

Eupraxia’s One-Year EoE Data Draw Fresh Analyst Attention Ahead of December Catalyst – ( $EPRX $IBB $SNY $XBI )

Eupraxia’s One-and-Done EoE Strategy Gains a 52-Week Tailwind -( $EPRX $IBB $REGN $SNY $XBI )

Iovance Biotherapeutics Raises 2026 Revenue Guidance as Amtagvi Demand Accelerates & Goldman Resumes Coverage – ( $GS $IOVA $XBI $IBB )

AbbVie’s JUVMO Approval Puts Parkinson’s Innovation Back in Motion And Serina Therapeutics Has a Timely Opening -( $ABBV $AMRX $SER $SUPN $IBB $XBI )

Biotech’s Durability Trade Is Getting Interesting: Kodiak, Eupraxia and Serina Put the Burden of Treatment in Focus -( $ABBV $EPRX $IBB $KOD $SER $XBI )

Your Guide To Staying Informed In The Markets